Quince Therapeutics Statistics
Total Valuation
QNCX has a market cap or net worth of $45.81 million. The enterprise value is -$15.50 million.
| Market Cap | 45.81M |
| Enterprise Value | -15.50M |
Important Dates
The next estimated earnings date is Monday, May 13, 2024, after market close.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
QNCX has 43.22 million shares outstanding. The number of shares has increased by 11.17% in one year.
| Shares Outstanding | 43.22M |
| Shares Change (YoY) | +11.17% |
| Shares Change (QoQ) | +14.00% |
| Owned by Insiders (%) | 17.06% |
| Owned by Institutions (%) | 28.16% |
| Float | 27.05M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.54 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.09, with a Debt / Equity ratio of 0.16.
| Current Ratio | 8.09 |
| Quick Ratio | n/a |
| Debt / Equity | 0.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -36.40% and return on invested capital (ROIC) is -33.43%.
| Return on Equity (ROE) | -36.40% |
| Return on Assets (ROA) | -28.80% |
| Return on Capital (ROIC) | -33.43% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$980,781 |
| Employee Count | 32 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -197,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.72% in the last 52 weeks. The beta is 1.25, so QNCX's price volatility has been higher than the market average.
| Beta (1Y) | 1.25 |
| 52-Week Price Change | -30.72% |
| 50-Day Moving Average | 1.17 |
| 200-Day Moving Average | 1.17 |
| Relative Strength Index (RSI) | 47.47 |
| Average Volume (30 Days) | 70,746 |
Short Selling Information
The latest short interest is 1.86 million, so 4.30% of the outstanding shares have been sold short.
| Short Interest | 1.86M |
| Short Previous Month | 1.86M |
| Short % of Shares Out | 4.30% |
| Short % of Float | 6.87% |
| Short Ratio (days to cover) | 37.67 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -33.04M |
| Pretax Income | -31.58M |
| Net Income | -31.39M |
| EBITDA | -31.26M |
| EBIT | -31.58M |
| Earnings Per Share (EPS) | -$0.84 |
Balance Sheet
The company has $75.06 million in cash and $13.75 million in debt, giving a net cash position of $61.31 million or $1.42 per share.
| Cash & Cash Equivalents | 75.06M |
| Total Debt | 13.75M |
| Net Cash | 61.31M |
| Net Cash Per Share | $1.42 |
| Equity / Book Value | 85.08M |
| Book Value Per Share | 1.97 |
| Working Capital | 67.87M |
Cash Flow
In the last 12 months, operating cash flow was -$18.29 million and capital expenditures -$70,000, giving a free cash flow of -$18.36 million.
| Operating Cash Flow | -18.29M |
| Capital Expenditures | -70,000 |
| Free Cash Flow | -18.36M |
| FCF Per Share | -$0.49 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
QNCX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.17% |
| Shareholder Yield | -11.17% |
| Earnings Yield | -68.51% |
| FCF Yield | -40.08% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |